Posner Brian S purchased $40K of DYN

Posner Brian S purchased 2,500 shares of Dyne Therapeutics, Inc. (DYN) at $16.00 on 2026-10-02.

Original reporting
SEC EDGAR · Posner Brian S
Published Oct 6, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 8:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$DYN
Neutral
high confidence
Mentioned
$DYN
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DYNNeutralLow
01

Why it matters

The filing provides a fresh, primary disclosure of a director's purchase, but the transaction size is trivial.

02

Market read

A small insider purchase with limited immediate price impact; primarily of interest to shareholders and analysts monitoring insider activity.

03

What to watch

Potential upcoming clinical trial milestones that may have prompted the insider purchase.

Relevance 4/10Novelty 4/10Timing: today

Background

SEC Form 4 filing discloses insider transactions; such filings are primary sources of corporate insider activity.

Company-level read

Ticker impact

$DYNNeutralHigh confidence
Context

Director Posner Brian S bought 2,500 shares for $40,000, increasing his stake to 27,000 shares.

Expected impact

modest upward pressure as the market prices in insider confidence

Evidence & confidence

The purchase is modest in size (<$1M) and unlikely to move the stock significantly, but insider buying is generally viewed positively.

Market effects

Minimal effect on the biotech sector; similar small insider trades are common.

No notable regional impact.

Limited to investors tracking Dyne Therapeutics.

Counterpoint

The purchase could be a routine portfolio rebalancing rather than a confidence signal.

Key entities

  • Dyne Therapeutics, Inc.

    Biotech firm developing gene therapies.

  • Posner Brian S

    Director of Dyne Therapeutics.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$DYNMedAI 8/10

Dyne Therapeutics Reports Q3 2026 Results; Advances DMD And DM1 Programs Ahead Of 2027 Milestones

Dyne Therapeutics (DYN) reported Q3 2026 net loss of $193.6M, up from $108.0M YoY. R&D and G&A expenses rose due to clinical trials and launch prep. The company expects cash to last until Q2 2028. Dyne's BLA for z-rostudirsen is under FDA priority review, with a PDUFA date of Jan 2027. Topline data for z-basivarsen is expected Q1 2027. DYN shares are down 1.78%.

$DYNMed

Dyne Therapeutics Q3 Loss Widens On Higher R&D Costs; Cash Runway Extends Into Q2 2028

Dyne Therapeutics (DYN) reported a wider Q3 2026 net loss of $193.6M ($1.06 per share) due to higher R&D and administrative expenses. Cash reserves are $1.134B, expected to last into Q2 2028. The company's z-rostudirsen BLA is under FDA priority review, with a PDUFA date of January 21, 2027. Topline ACHIEVE trial data for z-basivarsen are expected in Q1 2027. DYN stock is trading at $18.23, down 1.78%.

$DYNMed

Dyne Therapeutics 3Q 2026: EPS ($1.06) — 10-Q Summary

Dyne Therapeutics reported a wider net loss of $193.55M in 3Q 2026, up 79.1% YoY, due to increased R&D and administrative expenses. The FDA accepted its BLA for z-rostudirsen and set a PDUFA date for January 2027. The company also advanced its FORZETTO, Z-basivarsen, and FSHD programs.

$DYNMedAI 8/10

Why Dyne Therapeutics (DYN) Is Back In The Spotlight

Dyne Therapeutics (DYN) reported 1-year efficacy and safety data from its Phase 1/2 ACHIEVE trial, showing functional gains in myotonic dystrophy type 1. The stock has fallen 37% in 3 months but is up 84% over 3 years. Analysts suggest it's 57% undervalued at $36 per share, citing its FORCE platform's efficiency. Risks include potential trial failures and equity dilution.